J&J to build $1bn US CGT manufacturing site in Pennsylvania
The Pennsylvania site is one of four US-based manufacturing sites J&J plans to build over the next four years.
Cytiva Navigating cell therapy WP 4
REGENXBIO receives FDA response for RGX-121 application
Eli Lilly bets on in vivo cell therapy in $2.4bn Orna Therapeutics buyout
Sensorion announces $71.9m reserved offering to expand gene therapy pipeline
Eli Lilly outlays $1.12bn for hearing loss gene therapy partnership
iRegene receives FDA RMAT designation for NouvNeu001 to treat Parkinson’s
FDA increases manufacturing flexibility for cell and gene therapies
Cellenkos gains FDA orphan drug status for CK0804 to treat myelofibrosis
